Clinical trials: Anticoagulant
Adherence, Patient, Stroke, Ischemic
Electronic Monitoring and Improvement of Adherence to DOACs in Polymedicated Stroke Patients
Primary objective of the MAAESTRO trial is to evaluate the impact of an educational and reminder-based intervention on the adherence of stroke patients to DOACs.
- Trial name
- MAAESTRO (NCT03344146)
- Testing
- Medication intake reminders, Pillbox use and counselling
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- University Hospital, Basel, Switzerland
Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders
Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO
This prospective, randomized, controlled pilot trial aims to assess the safety and feasibility of Argatroban as an alternative anticoagulant to unfractionated heparin in patients receiving extracorporeal membrane oxygenation.
- Trial name
- NCT05226442
- Testing
- Argatroban, Unfractionated heparin
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Thrombosis
Vitamin K2 Intervention in Patients With Vitamin K Antagonists
The objective of the SAFE K study is to demonstrate that in patients treated with the antagonists of vitamin K (VKA), a daily intake of vitamin K2 (75 micrograms/day) as naturally produced by the ferments used in fermented dairy…
- Trial name
- SAFEK (NCT01533441)
- Testing
- Vitamin K2
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Danisco
Surgery, Oral, Hemorrhage
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
Aims: To investigate the incidence of bleeding complications during oral surgical procedures in patients medicated with DOACs. To investigate the perioperative and postoperative bleeding volume during oral surgical procedures in…
- Conditions
- Surgery, Oral, Hemorrhage, Postoperative Complications, Oral Surgical Procedures
- Trial name
- NCT04662515
- Testing
- Type of surgery, Dabigatran, Rivaroxaban
- Where
- 2 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Malmö University
Anticoagulants and Bleeding Disorders
DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic
New/direct oral anticoagulants (NOAC/DOAC), like apixaban and rivaroxaban, are an interesting alternative to unfractionated or low molecular weight heparin relayed by oral anti-vitamin K anticoagulants (VKA) for the treatment of…
- Trial name
- DAPHNE (NCT03112525)
- Testing
- CYP3A4/5 and P-gp phenotyping, CYP3A4/5 and P-gp genotyping
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University Hospital, Geneva
Ischemic Stroke, Intracranial Hemorrhage
Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)
The registry of acute stroke under new oral anticoagulants (RASUNOA) is a German multicenter, prospective, observational registry performed at about 50 study centers covering about 50.000 acute ischemic strokes and 6000 acute…
- Trial name
- RASUNOA (NCT01850797)
- Where
- Germany
- Volunteers
- 353 people
- Sponsor
- University Hospital Heidelberg
Atrial Fibrillation, Atrial Flutter
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-AF (NCT03129490)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 38 sites in Denmark
- Volunteers
- 11,000 people
- Sponsor
- Herlev and Gentofte Hospital
Intracranial Hemorrhage
Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage
The purpose of this dose-ranging pilot study is to compare Recombinant Activated Factor VII, Prothrombin Complex Concentrate and Fresh Frozen Plasma (each starting at low doses with escalation if necessary) for the reversal of…
- Trial name
- NCT00770718
- Testing
- Recombinant Activated Factor VII (rFVIIa), Prothrombin Complex Concentrate, Fresh Frozen Plasma
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Utah
Hemophilia
Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies
Life expectancy of haemophilia patients (specially severe) has dramatically increase in the last decades, which lead to the apparition of aging diseases such as cardiovascular disease, with the potential bleeding risk of…
- Trial name
- ERHEA (NCT03157154)
- Testing
- Non interventional study
- Where
- 6 sites in France
- Volunteers
- 259 people
- Sponsor
- Nantes University Hospital
Thrombosis, Venous
The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients
Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high…
- Trial name
- NCT06998745
- Testing
- Medication Therapy Management (MTM) model
- Where
- China
- Volunteers
- 327 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Atrial Fibrillation
Polish Atrial Fibrillation (POL-AF) Registry
Evaluation of clinical characteristics and pharmacotherapy of hospitalized Polish patients with atrial fibrillation (AF).
- Trial name
- POL-AF (NCT04419012)
- Testing
- observation
- Where
- Poland
- Volunteers
- 4,000 people
- Sponsor
- Jan Kochanowski University
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- NCT03786757
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)
ImproveR International (BI-001-IM)
The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting.
- Trial name
- NCT00290849
- Testing
- Bivalirudin
- Where
- Denmark
- Volunteers
- 4,000 people
- Sponsor
- Nycomed
Adherence, Medication, Statin Adverse Reaction
Medicines Gaps Study
The adherence project aims to understand adherence rates and barriers to Direct oral anticoagulants (DOACs) and statins and improve awareness of healthcare professionals on adherence across Leeds.
- Conditions
- Adherence, Medication, Statin Adverse Reaction, Anticoagulant Adverse Reaction
- Trial name
- MeGa (NCT05332158)
- Testing
- Questionnaires to report barriers to medication adherence
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Cardiac Event, Coronary Artery Disease
Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy
The study aims to conduct a randomized controlled trial among adults aged 19 years or older who have experienced acute myocardial infarction at least one year prior, or who have other comorbidities such as peripheral arterial…
- Conditions
- Cardiac Event, Coronary Artery Disease, Peripheral Artery Disease, Bleeding
- Trial name
- OACART (NCT07796217)
- Testing
- Aspirin and low-dose rivaroxaban, Clopidogrel with or without aspirin
- Where
- South Korea
- Volunteers
- 2,758 people
- Sponsor
- Seoul National University Bundang Hospital
Therapeutic Drug Monitoring
The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Short-term and Long-term Outcomes.
Non-vitamin K antagonist oral anticoagulant (NOAC) is the first line therapy to prevent thromboembolism in atrial fibrillation (AF) patients.
- Trial name
- NCT05283174
- Testing
- Blood sampling to test drug level
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Atrial Fibrillation
Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease
The study aims to depict the actual prescription patterns employed in clinical practice of patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e.
- Trial name
- PRODOAC (NCT06239402)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 394 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Atrial Fibrillation, Intracerebral Hemorrhage
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
Atrial fibrillation (AF) is the most common form of irregular heart rhythm. In people with AF, blood clots often form in the heart, which can travel to the brain.
- Trial name
- PRESTIGE-AF (NCT03996772)
- Testing
- Apixaban Oral Tablet, Dabigatran, Edoxaban Tablets
- Where
- 64 sites in Austria, France and 4 more
- Volunteers
- 319 people
- Sponsor
- Imperial College London
Prostheses and Implants, Stroke
Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
Mechanical heart valves (MHV) demand lifelong anticoagulation with vitamin K antagonists (VKA) due to the high thrombogenicity of the prosthesis.
- Conditions
- Prostheses and Implants, Stroke, Valve Heart Disease, Anticoagulants and Bleeding Disorders
- Trial name
- RIWA (NCT03566303)
- Testing
- Rivaroxaban 15 mg, Warfarin
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital Geral Roberto Santos
Antiphospholipid Syndrome
Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome
To Assess the Influence of Antiphospholipid Antibodies on INR Test Results in Patients with the Antiphospholipid Syndrome Anticoagulated with Vitamin-K Antagonists.
- Trial name
- NCT01660061
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Johann Wolfgang Goethe University Hospital